The White House denies a report suggesting President Donald Trump received retatrutide, an investigational obesity medication. Both outlets report that the White House response targets speculation that Trump could have obtained the drug through the FDA’s “compassionate use” pathway. Retatrutide is made by Eli Lilly and is not FDA approved, according to the reporting. MedPage Today says the White House “aggressively” denied the claim, which was based on information that Eli Lilly and the FDA granted one request related to compassionate use. The Hill similarly describes White House officials pushing back on the idea that Trump gained access via the FDA compassionate use program, noting that the drug remains investigational and that access in such programs is limited. The reports do not present new evidence from the White House beyond the denial itself, and they focus on clarifying whether any compassionate use authorization extended to Trump. Overall, the coverage centers on disagreement between a media report and the White House about whether Trump received the unapproved retatrutide drug.
White House denies report Trump accessed unapproved retatrutide obesity drug
The White House denies a report suggesting President Donald Trump received retatrutide, an investigational obesity medication. Both outlets report that the White House response targets speculation tha...
- The White House denies a report that President Trump received retatrutide, an investigational obesity drug.
- Retatrutide is not FDA approved, and is manufactured by Eli Lilly.
- Speculation in the report centers on the FDA compassionate use program as the mechanism for access.
- One compassionate use request was described as granted in connection with Eli Lilly and the FDA, according to the reporting.
- Both outlets report that White House officials dispute that Trump obtained the medication through compassionate use.
White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration’s (FDA) “compassionate use program.” The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one person gained access to the prescription through a program that...
2 months ago(MedPage Today) -- The White House aggressively denied a report that implied President Trump may have received the investigational obesity medication retatrutide. STAT on Tuesday reported that Eli Lilly and the FDA granted one request for compassionate...
2 months ago
Couple and their dog killed in alleged bear attack after final distress message
A couple and their border collie are reported to have been killed after an aggressive bear attacks their campsite, leavi...
Volunteers rescue climber stranded on Sierra Nevada ledge after 15-hour operation
Volunteers rescue a climber who is stranded on a small ledge in California’s Sierra Nevada. According to reports, the re...
Flood warnings issued in Nepal as Everest veterans join tunnel rescue mission
Fresh flood warnings are issued in Nepal as search and rescue operations continue after a major disaster, with authoriti...